Picture loading failed.

Anti-MS4A1 therapeutic antibody (Pre-made Veltuzumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma. As of December 2011, it is undergoing Phase I/II clinical trials. When used with milatuzumab it showed activity.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-617-1mg 1mg 3090
GMP-Bios-ab-617-10mg 10mg 21890
GMP-Bios-ab-617-100mg 100mg 148000
GMP-Bios-ab-617-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-MS4A1 therapeutic antibody (Pre-made Veltuzumab biosimilar,Whole mAb)
INN Name Veltuzumab
TargetMS4A1
FormatWhole mAb
DerivationHumanized
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2007
Year Recommended2008
CompaniesImmunomedics;Weill Cornell Medical College
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedChronic lymphocytic leukaemia;Rheumatoid arthritis;Idiopathic thrombocytopenic purpura;Non-Hodgkin's lymphoma;Follicular lymphoma
Development Techna